原发性肝癌患者肿瘤组织生长抑素受体表达与血AFP水平的相关性  

Correlation of Somatostatin Receptor Expression in Human Hepatocellular Carcinoma Tissue to Serum Alpha-fetoprotein Concentration

作　　者：谢咏梅[1] 严律南[2] 魏兵[3] 郭梅梅[1] 唐承薇[1] 

机构地区：[1]四川大学华西医院消化内科,四川成都610041 [2]四川大学华西医院肝胆外科,四川成都610041 [3]四川大学华西医院病理科,四川成都610041

出　　处：《癌症》2007年第7期688-692,共5页Chinese Journal of Cancer

基　　金：国家自然科学基金(No.30330270)~~

摘　　要：背景与目的:生长抑素类似物(somatostatin analogue,SSTA)对部分原发性肝癌(hepatocellular carcinoma,HCC)患者具有一定疗效,但HCC患者肿瘤组织中生长抑素受体(somatostatin receptor,SSTR)表达状况不详,其与血甲胎蛋白(alpha-fetoprotein,AFP)的相关性也未见探讨。本研究拟了解肝癌组织中SSTR1、SSTR2、SSTR3、SSTR4及SSTR5亚型的表达状况及其与血AFP的相关性。方法:逆转录-聚合酶链反应及免疫组织化学法分别检测人肝癌及肝硬化组织(各40例)SSTR1、SSTR2、SSTR3、SSTR4及SSTR5亚型的mRNA及蛋白表达;酶联免疫吸附试验检测HCC患者肿瘤组织及外周血AFP水平。结果:肝癌组织中SSTR1、SSTR2、SSTR3、SSTR4及SSTR5蛋白阳性率(分别为47.5%、70.0%、50.0%、65.0%及67.5%)显著高于肝硬化组织(分别为55.0%、67.5%、52.5%、60.0%及47.5%)。肝癌组织中SSTR1、SSTR2、SSTR3、SSTR4及SSTR5表达与患者血AFP水平呈二次曲线正相关(r依次为0.882、0.901、0.877、0.854、0.903,P<0.05)。血AFP水平在200～800!g/L范围时,伴有肝癌组织SSTRs的高表达,过低或过高的血AFP水平伴有SSTR低表达。结论:约60%HCC患者的肿瘤组织表达了SSTRs,其表达量明显高于肝硬化组织;血AFP水平在200～800"g/L的HCC患者伴有肝癌组织SSTRs的高表达,提示为SSTA治疗的适宜候选者。BACKGROUND ＆ OBJECTIVE： Somatostatin analogue（SSTA） has inhibitory effect on the growth of hepatocellular carcinoma （HCC）. However, the expression of somatostatin receptor （SSTR） in HCC is still unclear and its correlation to serum alpha-fetoprotein （AFP） has not yet been explored. This study was to investigate the expression of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 subtypes in HCC, and explore their correlations to serum AFP concentration. METHODS：The mRNA and protein expression of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 subtypes in 40 specimens of HCC and 40 specimens of liver cirrhosis were detected by reverse transcription-polymerase chain reaction （RT-PCR） and immunohistochemistry （IHC）, respectively. AFP levels in liver tissues and peripheral blood of the 40 HCC patients were measured with enzyme-linked immunosorbent assay （ELISA）. RESULTS. The positive rates of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 proteins were 47.5%, 70.0%, 50.0%, 65.0%, and 67.5% in HCC, and 55.0%, 67.5%, 52.5%, 60.0%, and 47.5% in liver cirrhosis tissues, respectively. The protein levels of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 were markedly higher in HCC than in liver cirrhosis tissues. The expression of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 in HCC had curilinear correlations with serum AFP levels （r= 0.882, 0.901, 0.877, 0.854, 0.903, respectively, P 〈 0.05）. Serum AFP levels ranging between 200-800 ng/ml were associated with high expression of SSTRs in HCC; serum AFP levels below or over that range were associated with low expression of SSTRs. CONCLUSIONS： About 60% of the HCC tissues express SSTRs; the protein levels of SSTRs are much higher in HCC than in liver cirrhosis tissues. HCC patients with serum AFP level ranging between 200-800 ng/ml may be good candidates for SSTA therapy.

关 键 词：肝肿瘤 生长抑素受体 甲胎蛋白 

分 类 号：R735.7[医药卫生—肿瘤]